We are live on ! Find out more
SCNI

Scinai Immunotherapeutics
SCNI

11 hedge funds and large institutions have $153K invested in Scinai Immunotherapeutics in 2022 Q3 according to their latest regulatory filings, with 1 funds opening new positions, 1 increasing their positions, 3 reducing their positions, and 3 closing their positions.

New
Increased
Maintained
Reduced
Closed

0.67% less ownership

Funds ownership: 1.79% → 1.13% (-0.67%)

15% less funds holding

Funds holding: 13 → 11 (-2)

61% less capital invested

Capital invested by funds: $389K → $153K (-$236K)

67% less first-time investments, than exits

New positions opened: 1 | Existing positions closed: 3

67% less repeat investments, than reductions

Existing positions increased: 1 | Existing positions reduced: 3

Holders
11
Holders Change
-2
Holders Change %
-15.38%
% of All Funds
0.19%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
1
Increased
1
Reduced
3
Closed
3
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Millennium Management
Millennium Management
New York
+$13.5K
2
UBS Group
UBS Group
Switzerland
+$3.38K

Top Sellers

Rank Fund Capital Flow
1
Envestnet Asset Management
Envestnet Asset Management
Illinois
-$94.5K
2
Citadel Advisors
Citadel Advisors
Florida
-$28K
3
Susquehanna International Group
Susquehanna International Group
Pennsylvania
-$13K
4
Morgan Stanley
Morgan Stanley
New York
-$11.3K
5
TPWA
TRUE Private Wealth Advisors
Oregon
-$10.1K

SCNI Hedge Fund Activity: Q3 2022 in Review

11 of the 5,828 institutional investors tracked by Wall St. Rank reported a position in Scinai Immunotherapeutics (SCNI) for Q3 2022, worth a combined $153K — down 61% from $389K a quarter earlier.

Sellers outnumbered buyers: 3 funds closed out of SCNI and 1 opened new positions — a net loss of 2 holders — while 3 trimmed existing stakes and 1 added.

The largest buyer was Millennium Management, opening a new position worth an estimated $13.5K. The largest seller was Envestnet Asset Management, cutting an estimated $94.5K.

  • 11 institutional investors held Scinai Immunotherapeutics (SCNI) as of Q3 2022, down from 13 in Q2 2022.
  • Funds reported $153K of Scinai Immunotherapeutics stock for Q3 2022, down 61% quarter-over-quarter.
  • 1 fund opened new Scinai Immunotherapeutics positions in Q3 2022 and 3 closed out, a net change of -2 holders.
  • The largest Scinai Immunotherapeutics buyer in Q3 2022 was Millennium Management, an estimated $13.5K added.
  • The largest Scinai Immunotherapeutics seller in Q3 2022 was Envestnet Asset Management, an estimated $94.5K sold.

Based on aggregated 13F filings for Q3 2022.